Correlation Between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients With Advanced Solid Tumors: A Pilot Study

Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoli-posomal irinotecan (nal-IRI). Experimental Design: Eligible patients with previously trea-ted solid tumors had FMX-MRI scans before and…   Read More

Imaging Endpoints Featured Speaker at 2nd Annual Immuno-Oncology 360°

Immuno-Oncology 360°

Imaging Endpoints CMO and Founder, Ronald Korn, MD., PhD. presents “Imaging the Immune System in Solid Tumors.”This talk will cover the spectrum of immunotherapy from an imaging perspective along with current trends including novel imaging methodologies and enhanced techniques beyond conventional imaging. The Immuno-Oncology 360° eventdelves into key areas of business, clinical and scientific advancements including the Business Aspects for IO, Differences of Modalities in Immunotherapy, Methodological Advances – Investigating Immunotherapies in the Clinic, Immunotherapy Practice Altering Clinical Advances, Hematologic Malignancies, Emerging Biomarkers and Randomized Phase II Combination Therapy Trials.  Visit us and learn how we can provide imaging expertise to help develop your product in translational and Phase I studies and provide core lab services for Phase I, II, III and IV. For more information, email us at or call us at 480.314.3070.

February 2, 2016 – February 3, 2016